Brought to you by 
Catabasis Pharmaceuticals nets $64.2mm in IPO
14 Aug 2015
Executive Summary
Catabasis Pharmaceuticals Inc. (developing therapeutics based on its "Safely Metabolized And Rationally Targeted" (SMART) linker technology platform) netted $64.2mm through the sale of 5.8mm shares (including the overallotment) at $12 (up-sized but below $13-15 filing range) in its IPO.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Catabasis Pharmaceuticals nets $64.2mm in IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice